Comparing two oral medicines for children with relapsing MS
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests two oral medications, diroximel fumarate and dimethyl fumarate, in children and teens with relapsing MS. It aims to see if they are safe and can reduce the number of relapses compared to each other.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be under 18 and have a doctor's diagnosis of pediatric multiple sclerosis.
- You must have had at least one MS relapse in the last year, or two relapses in the last two years, or an MRI showing active brain lesions.
- You must be able to walk and manage daily activities with some help (EDSS score between 0 and 5).
- You must not have a type of MS that gets steadily worse without relapses.
- You must not have other conditions like certain autoimmune diseases, severe allergies, cancer, or certain stomach/bowel problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two oral medications, ozanimod and fingolimod, to see which one works better and is safer for children and teenagers with relapsing-remitting MS. Both drugs help reduce MS attacks and slow down the disease.
This trial tests a new drug called ublituximab to see if it can reduce flare-ups in children and teens who have relapsing multiple sclerosis. It aims to understand if the treatment is safe and effective for younger patients.
This study tests different approved “disease-modifying” MS medicines (shots and pills) in adults with relapsing multiple sclerosis that is currently active. It mainly looks at outcomes based on how newly starting—or recently started—treatments are handled for people with recent relapses and mild disability.
This study tests an oral medication, dimethyl fumarate, which is already used for multiple sclerosis. It aims to see how well it controls relapses in people with relapsing forms of MS. If you have had a relapse in the last year, you might be eligible.
This trial tests if it's safe to stop or reduce anti-CD20 treatment after several years of stable disease, compared to continuing it. It's for people with relapsing-remitting MS who are at least 40 years old and have had no MS activity for the past 3 years on anti-CD20 therapy.
This study tests a new oral medication called Rocbrutinib for people with relapsing-remitting multiple sclerosis (RRMS). The drug targets a protein that may help reduce the immune system's attack on the brain and spinal cord. The trial will check if the medication can reduce new brain lesions and slow down disability progression.
Hear when a new Relapsing Forms of Multiple Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.